^
    Back
    Association details:
    Biomarker:CD22 expression
    Cancer:B Acute Lymphoblastic Leukemia
    Drug:Besponsa (inotuzumab ozogamicin) (DNA replication inhibitor, CD22-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia

    Excerpt:
    ...- Leukemic blasts must demonstrate surface expression of CD22 at the time of relapse by local/institutional flow cytometry of a bone marrow aspirate sample; (assessment of CD22 using a bright fluorophore such as phycoerythrin [PE] is strongly recommended)...
    Trial ID:
    AALL1621
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia

    Excerpt:
    ...CD22 expression will be determined by multiparameter flow cytometry (MFC) or immunohistochemistry....
    Trial ID:
    NCT03991884
    Less C2 evidence
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    EHA 2023
    Title:

    INOTUZUMAB OZOGAMICIN TREATMENT IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY PHILADELPHIA CHROMOSOME-NEGATIVE CD22-POSITIVE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA: A REAL-LIFE FRENCH STUDY

    Published date:
    05/11/2023
    Excerpt:
    CD22-positive B-cell precursor acute lymphoblastic leukemia (BCP-ALL)...This retrospective study was designed to provide a description of the characteristics and outcome of InO treated adult patients with R/R Philadelphia chromosome negative (Ph-) BCP ALL...Overall response rate was 68% including 12 complete remission (CR) and 3CR with incomplete hematologic recovery (CRi).